原发性小肠淋巴瘤6例临床分析并文献复习

目的：探讨原发性小肠淋巴瘤临床特点,诊断及治疗方法。方法：对1997—2012年确诊的6例原发性小肠淋巴瘤患者的临床资料进行临床分析,总结其临床特点,同时复习相关文献。结果：隐性失血、脐周隐痛、腹部肿物、隐匿消瘦是原发性小肠淋巴瘤的最常见表现,而以全身症状为主的很少。推进式小肠镜及胶囊内镜的应用对该病诊断有重要价值,但阳性率较低。MSCT和MRE对本病的诊断有重要辅助作用。本组患者病理结果均为非霍奇金淋巴瘤,其中B细胞型4例,T细胞型2例,4例发生淋巴转移。6例患者中4例行手术切除治疗,2例行单纯化疗,2例死亡。结论：选择有效的检查手段,可提高小肠肿瘤的术前诊断,降低其误诊误治的发生率。手术切除是治疗该疾病的主要手段,采用手术后配合化疗及放疗的综合治疗可提高患者的生存率。     

原发性肝透明细胞癌影像学及临床分析

目的:探讨原发性肝细胞癌(PCCCL)的影像学及临床病理等特点,提高对肝透明细胞癌的认识,早期确诊、早期治疗、改善预后等,以避免临床误诊,并评价PCCCL的预后比例及疗效。方法:回顾性分析了2009年至2010年我院肿瘤科收治的3例肝透明细胞癌患者的临床资料、影像学质料,以及临床治疗和随访情况。结果:3例均为男性,2例行氩氦刀靶向消融治疗,1例行CT引导下射频消融治疗,术后随访半年2例过世,1例生存。结论:原发性肝细胞癌透明细胞型早期诊断尤为重要,及时手术切除及消融治疗是取得较好疗效的关键。     

原发性肾上腺非霍奇金淋巴瘤（附9 例报告）

目的:探讨原发性肾上腺淋巴瘤(Primary Adrenal Lymphoma,PAL)的临床特点、提高对PAL的认识。方法:回顾分析解放军总医院1995年12月至2007年6月收治的9例PAL的临床表现、实验室检查、影像学特点、组织病理类型以及治疗方法等临床资料,并结合国内外文献进行分析。结果:9例患者中,1例因常规体检发现,8例因腹痛、腹胀或腰痛就诊发现;其中单侧3例,双侧6例,实验室检查无明显异常,影像学检查仅发现肾脏肿瘤,但术后病理组织学诊断为非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL),其中8例弥漫大B细胞淋巴瘤,1例T细胞淋巴瘤;7例患者术后均接受了CHOP或RCHOP方案化疗为主的综合治疗,2例常规治疗;随访至2010年2月,1例弥漫性大B细胞淋巴瘤患者存活4年,1例在术后3年2个月死亡,余7均在2年内死亡。结论:PAL是一种罕见的、恶性程度较高的肿瘤,临床表现和影像学检查缺乏特异性,组织病理学及免疫组织化学是明确诊断的好方法。术前确诊肾上腺原发性非霍奇金淋巴瘤可避免手术,联合化疗应为治疗首选。     

原发性腹膜后肿瘤46例诊疗分析

目的:总结并探讨原发性腹膜后肿瘤(PRPT)的诊断及治疗方法。方法:回顾并分析2004年1月至2009年12月收治的46例腹膜后肿瘤患者的临床资料及随访结果。结果:良性肿瘤17例,完整切除15例,部分切除2例,复发4例,均再次手术;恶性肿瘤29例,完整切除10例,部分切除15例,活检2例,复发6例,再次手术4例。随访时间0.5至5年,良性肿瘤死于其他疾病3例,死于原发性腹膜后肿瘤1例;恶性肿瘤死亡22例,其中1年内死亡8例,3年内死亡12例,5年内死亡2例。结论:对原发性腹膜后肿瘤,B超、CT及MRI检查是目前诊断PRPT方便、有效的诊断手段,手术治疗是治疗PRPT的首选治疗方式,完整切除肿瘤是影响PRPT治疗效果及其预后的重要因素。对于复发病例应选择再次手术治疗。     

原发性腹膜后肿瘤46例诊疗分析

目的：总结并探讨原发性腹膜后肿瘤（PRPT）的诊断及治疗方法。方法：回顾并分析2004年1月至2009年12月收治的46例腹膜后肿瘤患者的临床资料及随访结果。结果：良性肿瘤17例,完整切除15例,部分切除2例,复发4例,均再次手术;恶性肿瘤29例,完整切除10例,部分切除15例,活检2例,复发6例,再次手术4例。随访时间0.5至5年,良性肿瘤死于其他疾病3例,死于原发性腹膜后肿瘤1例;恶性肿瘤死亡22例,其中1年内死亡8例,3年内死亡12例,5年内死亡2例。结论：对原发性腹膜后肿瘤,B超、CT及MRI检查是目前诊断PRPT方便、有效的诊断手段,手术治疗是治疗PRPT的首选治疗方式,完整切除肿瘤是影响PRPT治疗效果及其预后的重要因素。对于复发病例应选择再次手术治疗。     

早期肺癌诊断中PET/CT的应用价值

目的:探讨PET/CT在早期肺癌诊断中的应用价值.方法:应用PET/CT对16例肺部孤立性病灶进行PET/CT检查,手术切除病灶组织送病理检查,以判断诊断符合率与细胞类型.结果:16例肺病灶患者PET/CT检查与手术切除组织病理结果相比较,诊断符合率为87.5%,其中腺癌13例(包括细支气管肺泡细胞癌6例),鳞癌2例,肺粘膜相关B细胞淋巴瘤1例.结论:结合临床症状,PET/CT检查能够准确的对肺癌做出早期诊断,及早治疗,改善患者预后     

原发性胃淋巴瘤临床与内镜特征分析

目的:探讨影像学检查及胃镜、超声内镜对原发性胃淋巴瘤的术前诊断方法,以提高该疾病的术前诊断率。方法:总结我院经手术及病理证实的21例原发性胃淋巴瘤资料,评估胃镜活检、超声内镜及CT对该病诊断的作用。结果:21例术前CT检查,误诊为浸润型胃癌11例,间质瘤2例,未见明显异常3例。CT术前诊断率为23.8%(5/21)。全部患者均实施胃镜检查,活检病理诊断淋巴瘤14例,胃镜活检诊断率为66.7%(14/21)。其中10名患者实施超声胃镜检查,判断胃淋巴瘤6例、胃癌3例、间质瘤1例;术前诊断率为60.0%(6/10)。结论:胃镜及超声内镜是原发性胃淋巴瘤的主要术前诊断方式;CT扫描能明确有无纵隔及腹腔内淋巴结肿大,为原发性胃淋巴瘤提供诊断依据。     

EGFR突变与EML4-ALK融合共存的非小细胞肺癌的临床病理特征及治疗分析

目的:探讨表皮生长因子受体(EGFR)基因突变与棘皮动物微管相关样蛋白4与间变性淋巴瘤激酶(EML4-ALK)融合基因共存(以下简称双基因异常)的非小细胞肺癌的临床病理特征及治疗策略。方法:回顾性收集并分析2012年1月至2016年12月我院收治的EGFR突变与EML4-ALK融合基因共存的非小细胞肺癌患者的临床资料及病理特点。结果:11例双突变非小细胞肺癌占医院同期入院非小细胞肺癌患者的0.68%(11/1620);男性6例,女性5例;年龄23-70岁,平均年龄51.6岁;11例患者均不吸烟;腺癌9例,肉瘤样癌2例;临床分期,ⅠA期3例,ⅡB期1例,ⅢA期1例,ⅢB期1例,ⅠV期5例;6例行手术治疗,4例使用传统化疗,最好疗效为稳定(SD),最长无进展生存期(PFS)为6月;5例患者使用表皮生长因子酪氨酸激酶抑制剂(EGFR-TKⅠ)治疗,使用EGFR-TKⅠ最好疗效为部分缓解(PR),PFS为3-23月,中位PFS为9月;截止2017年12月,死亡4例,11例患者的生存时间为1-67月,中位存活时间为21月。结论:EGFR基因突变与EML4-ALK融合基因共存型非小细胞肺癌临床少见,多见于不吸烟或少吸烟的肺腺癌患者,双基因异常的非小细胞肺癌的靶向药物的治疗缺乏统一性,有待进一步研究,基于EGFR及EML4-ALK的磷酸化水平或肿瘤突变负荷选择靶向药物的个体化精准治疗是非常重要的。     

原发性胃T细胞淋巴瘤的临床病理分析

目的分析探讨原发于胃的外周T细胞淋巴瘤(Primary gastric T cell lymphoma,PTCL)的临床病理特征、免疫表型及分子生物学特点。方法回顾分析我院自2009~2012年收治的经免疫组化证实的PTCL患者4例。结合临床表现、形态学特征、发病机制和免疫表型,对其进行分析,并对鉴别诊断、治疗和预后的情况进行讨论。结果原发于胃的PTCL临床表现为腹胀、腹痛、腹部包块;镜下见形态较单一的肿瘤性淋巴细胞弥漫分布,穿插于肌间;免疫表型肿瘤细胞均表达T细胞标记,部分病例细胞毒标记(TIA-1)可阳性。治疗手段以手术切除辅以联合化疗为主,预后较差。结论 PTCL原发于胃非常罕见,这是一类异质性很强的肿瘤,必须结合临床、病理组织特征和免疫组织化学特征进行诊断和鉴别诊断。     

细胞蜡块诊断淋巴瘤18例

目的探讨18例浆膜腔积液中细胞学诊断淋巴瘤的临床病理学特征、免疫表型、诊断及鉴别诊断、治疗及预后。方法收集武汉大学人民医院2016年1月—2018年12月间由浆膜腔积液诊断为淋巴瘤患者18例,通过常规液基涂片、制作细胞蜡块、HE染色及免疫细胞化学染色,个别病例采用基因重排检测或流式细胞学检查,并部分对照其细胞学诊断和活检组织病理诊断的符合率。结果 18例均行免疫细胞化学检测,结果均为非霍奇金淋巴瘤。其中无淋巴瘤病史的有12例:包括4例弥漫性大B细胞淋巴瘤;1例淋巴浆细胞样淋巴瘤;1例浆细胞瘤;2例T淋巴母细胞淋巴瘤;1例NK/T细胞淋巴瘤;1例外周T细胞淋巴瘤,非特殊类型;2例T细胞淋巴瘤。其余6例均有淋巴瘤病史,其中4例为弥漫性大B细胞淋巴瘤,2例为血管免疫母细胞性T细胞淋巴瘤。结论浆膜腔积液是淋巴瘤的较常见并发症,细胞病理学诊断淋巴瘤难度虽相对较大,但通过制备细胞蜡块,在镜下观察肿瘤细胞成分单一,表现为大量散在分布的不成熟淋巴样细胞,细胞之间无黏附性,同时结合免疫细胞化学染色等相关检测方法,可明确诊断,值得推广。     

小肠CT及双气囊小肠镜诊断克罗恩病患者的差异性分析

目的:探究小肠CT及双气囊小肠镜诊断克罗恩病患者的差异性。方法:选择2017年4月至2019年3月于我院接受治疗的60例克罗恩病患者,分别实施小肠CT及双气囊小肠镜检测,对比两种检测方式对克罗恩病患者诊断准确率及病变范围、病变位置、活动度和并发症的检测差异。结果:CT检出克罗恩病的准确率96.67%,双气囊小肠镜检出克罗恩病的准确率为93.33%,其差异无统计学意义(P>0.05)。小肠CT主要表现为肠腔狭窄50例(83.33%),肠壁增厚52例(86.67%),肠外淋巴结46例(76.67%),肠系膜水肿及血管改变21例(35.00%),肠外炎症10例(16.67%),瘘管3例(5.00%),瘘道1例(1.67%);双气囊小肠镜表现为环形溃疡、不规则溃疡、环状溃疡等共计46例(76.67%),阿弗他溃疡22例(36.67%),黏膜充血、水肿等26例(43.33%),结节样增生6例(10.00%),小肠肠腔节段性狭窄16例(26.67%),假性息肉9例(15.00%);经病理学检测表现为淋巴细胞、中性粒细胞、嗜酸性粒细胞等炎性浸润,淋巴组织及肉芽组织出现增生小肠CT发现肠外炎症、瘘道、瘘管等合计14例,而双气囊小肠镜未发现并发症。结论:相比于双气囊小肠镜,小肠CT能够更为准确的判断克罗恩病患者是否处于炎症状态,也能够更有效的发现肠外并发症的存在,但小肠CT及双气囊小肠镜联合应用监测效果更佳。     

原发性十二指肠恶性肿瘤的临床分析

目的:探讨原发性十二指肠恶性肿瘤的临床特点、诊断方法和预后影响因素。方法:回顾性分析随访资料完整的45例原发性十二指肠恶性肿瘤患者的临床病理资料。结果:腺癌33例(73.3%)为主要的病理类型。主要临床表现为腹痛、上腹部不适、黄疸、消化道出血等。胃十二指肠镜、内镜逆行胰胆管造影(Endoscopic Retrograde Cholangio-Pancreatography,ERCP)、十二指肠低张造影、超声内镜、CT及B超确诊率分别为91.1%(41/45),93.3%(42/45),82.2%(37/45),75.6%(34/45),68.9%(31/45)及26.7%(12/45)。本组45例均行开腹手术,包括根治性手术,胰十二指肠切除术36例;姑息性手术,胃肠吻合术2例、肿瘤局部切除术5例、短路手术2例。根治术和姑息术后5年生存率分别为46.7%和4.4%,两组生存率差异有统计学意义(P<0.05)。对全组45例患者的预后因素进行Cox回归分析的结果显示,手术方式、肿瘤浸润深度和淋巴节转移是影响预后的独立危险因素(均P<0.05)。结论:原发性十二指肠恶性肿瘤缺乏特异性临床表现;胃十二指肠镜、ERCP以及十二指肠低张造影等联合检查可提高诊断率;根治性手术远期疗效较好;淋巴结转移和局部侵犯是肿瘤预后不良的重要影响因素。     

252 例胸膜恶性肿瘤的临床病理分析

目的：探讨胸膜恶性肿瘤的病理类型、肿瘤所占比例、临床病理特征及鉴别诊断。方法：结合病理形态学及免疫组化方法对 252 例胸膜恶性肿瘤进行诊断及鉴别诊断。结果：252 例胸膜恶性肿瘤包括胸膜穿刺活检120 例,胸腔镜活检25 例,伴有胸膜转 移的恶性胸水107 例;男性143 例,女性109 例,年龄19-87 岁,平均年龄59.9 岁。临床主要症状是胸闷、气短、咳嗽、胸痛等。CT 表现为胸膜增厚、胸水(90%)、多发或单发胸膜结节和原发器官占位性病变。活检病例中,转移性癌86 例(34.1%),包括肺腺癌64 例(25.4%),小细胞癌11 例(4.4%),鳞癌11 例(4.4%),恶性间皮瘤47 例(18.7%),滑膜肉瘤9 例(3.6%),非霍奇金淋巴瘤3 例(1.2%); 恶性胸水病例病例中转移性癌95 例(37.7%),包括肺腺癌85 例(33.7%),小细胞癌6 例(2.4%),鳞癌2 例(0.8%),乳腺腺癌2 例 (0.8%),恶性间皮瘤8 例(3.2%),非霍奇金淋巴瘤4 例(1.6%)。结论：胸膜恶性肿瘤中以转移性腺癌多见,其次为恶性间皮瘤,结合 形态学及免疫组织化学检测不同标志物的表达有助于诊断胸膜恶性肿瘤的种类。     

Imaging Findings of Primary Splenic Lymphoma: A Review of 17 Cases in Which Diagnosis Was Made at Splenectomy

Purpose

This study sought to characterize the imaging features of primary splenic lymphoma (PSL).

Materials and Methods

Pathological and imaging data from 17 patients with primary splenic lymphoma initially diagnosed at splenectomy were retrospectively analyzed. Pretreatment computed tomography (CT) imaging was available for 16 patients, and magnetic resonance imaging (MRI) data were available for 4 patients. Splenic lymphoma imaging data were categorized based on the gross pathological presentation in the following manner: type 1, homogeneous enlargement; type 2, miliary nodules; type 3, multifocal masses of varying size; and type 4, solitary large mass.

Results

Of the 17 patients with PSL, 16 cases were non-Hodgkin lymphoma, and of these, 9 cases were diffuse large B cell lymphomas (DLBCL) and 4 cases were splenic marginal zone B-cell lymphoma (SMZL). Imaging showed the following types of PSL presentation: 1 case of type 1, 0 cases of type 2, 4 cases of type 3, and 12 cases of type 4. There was evidence of necrosis in 12 cases (70.6%), and there was evidence of mild enhancement in enhanced CT in 14 cases and in enhanced MRI in 3 cases. Prior to surgery, PSL was considered possible in 8 patients.

Conclusion

The most frequent histological subtype was DLBCL, followed by SMZL. In both CT and MRI, PSL generally presents as a solitary mass or masses rather than as splenomegaly. In addition, necrosis and mild enhancement are commonly observed, and splenectomy may be required to confirm the diagnosis.     

Apport de la TEP/TDM au FDG en cancérologie de l’intestin grêle

This article focuses on the indication for FDG PET/CT in case of tumours of the small intestine, neuro-endocrine tumours excluded. The adenocarcinomas, lymphomas and sarcomas (including stromal tumours or GIST) are studied. There is no specific recommendation for FDG PET/CT in adenocarcinomas, extremely rare in comparison with colorectal adenocarcinomas. However, the utility of FDG PET/CT has been reported in clinical cases for detection and staging, especially in patients with high risk of developing the disease (Crohn's disease being the most important risk factor). The primary lymphomas of the small gut are also very rare, corresponding in all cases to non-Hodgkin lymphomas, for which the role of FDG PET/CT is recognised in follicular lymphoma, large B-cell lymphoma and Burkitt lymphoma. The stromal tumours correspond to the most frequent sarcomas. Stromal tumours in the small intestine are less frequent in the small intestine than in the stomach. The role of FDG PET/CT is well established in stromal tumours for the staging of the disease and for determining the efficacy of therapy with tyrosine kinase inhibitor. FDG PET is especially effective to evaluate the response since the radiologic criteria are difficult to assess, based not on the decrease of size of the lesions but on the decrease of density and of contrast enhance.     

Immunoproliferative Small Intestinal Disease and B-Cell MALT Lymphoma of the Digestive Tract

Immunoproliferative small intestinal disease (originally called Mediterranean lymphoma and subsequently alpha chain disease) is a slowly progressive low grade primary small intestinal B-cell lymphoma characterized by the synthesis of a truncated alpha heavy chain without light chain by the neoplastic cells. The histological features of IPSID and low grade primary gastric B-cell lymphoma are closely similar and recapitulate the those of Peyer''s patches. This observation has led to the mucosa associated lymphoid tissue (MALT) lymphoma concept which encompasses a group of extranodal lymphomas including IPSID and primary gastric lymphoma. Unlike nodal low-grade B-cell lymphomas, IPSID and low grade gastric lymphoma remain localized to their sites of origin for prolonged periods. One possible explanation for this is that the growth of these lymphomas is influenced by a local antigen. This is supported by reports of clinical remissions induced in IPSID following sterilization of the small intestine using broad spectrum antibiotics. Similar findings have been reported in low grade gastric lymphoma following eradication of Helicobacter pylori which is almost invariably present in the patients'' stomachs. Laboratory experiments have shown that the growth of lymphomatous B-cells is stimulated via H. pylori specific T-cells. Further work is required to identify the antigen(s) operative in IPSID and, possibly, other low grade B-cell lymphomas.     

Angiocentric T-cell lymphoma

SUMMARY: The CD20+ variant of angiocentric T-cell lymphoma is an unusual type of T-cell lymphomas that present cystic changes in organs because of ischaemic necroses. The purpose of this study was to describe a case of CD20+angiocentric T-cell lymphoma, discussing its clinical, histopathological and immunohistochemical features, to analyze its proliferation kinetics and to consider its possible relationship to the Epstein-Barr virus (EBV) to understand better the pathobiological nature of the disease. METHODS: The clinical, histopathological, immunohistochemical and single-cell DNA cytophotometric features of the case were analyzed. In addition in situ hybridization was performed to detect EBV. RESULTS: The 24 years old woman was admitted to our Institute because of pain in the abdominal region and weight loss. There were enlarged lymph nodes on the neck, and biopsy was done. Histological diagnosis: angiocentric T-cell lymphoma, CD20+ variant. CD3, CD43, CD45RA and CD45R0 antigens were positive in the atypic lymphoid cells of the tumour and in cells infiltrating the vascular wall. DNA index was 0.8589 (hypodiploid). Tumour cells in G1 phase: 47%, S phase: 45.4%, G2 phase: 7.6%. Combined chemotherapy was administered because of clinical stadium IV/B of malignant lymphoma (5 CHOP-Bleo, CEPP, CEP, CMVE treatment). The disease showed gradual progression and the patient died 14 months after the first symptoms had appeared. CONCLUSIONS: In the last 13 years there were 5 cases of angiocentric T-cell lymphoma at our Institute. The CD20+ variant is rare, its clinical symptoms are special, the prognosis is unfavourable. The cause why we demonstrate this case is to call attention to a new treatment for these patients by immunotherapy using monoclonal antibodies against CD20 antigen.